GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Plandai Biotechnology PLPL · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

—

FY2015FY2026

Net income

−$51,401

FY2015FY2026

Free cash flow

—

FY2015FY2026

Shareholders' equity

—

FY2015FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2017FY2016FY2015
Revenue———$298,494———$411,989$92,898$92,898
Gross profit———−$645,000———−$1.8m−$693,000−$692,531
Research and development———————$4,025$24,666$24,666
Operating income−$51,401−$57,446−$3.8m−$705,501−$24,273−$105,000—−$3.1m−$8.8m−$8.8m
Net income−$51,401−$2,446$16.0m−$19.8m$6.8m−$397,000−$83,481−$4.0m−$9.6m−$9.6m
Diluted earnings per share-0.00-0.000.00-0.000.00-0.00-0.00-0.02-0.04-0.06

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2017FY2016FY2015
Total assets——$100,000——$7.3m$7.3m$6.8m$6.5m$8.5m
Cash and short-term investments———————$6,896$12,915$33,619
Total liabilities——$155,000$442,644$1.5m$9.2m$26.2m$21.8m$18.4m$16.8m
Debt——$155,000$50,175$114,963$7.0m$21.7m$17.1m$14.3m$14.5m
Shareholders' equity——−$55,000−$442,644−$1.5m−$9.2m−$16.9m−$13.4m−$9.8m−$6.5m
Shares outstanding44,890m44,890m44,889m8,486m7,344m6,408m1,313m263m252m167m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2017FY2016FY2015
Cash from operations——$15.6m$558,114$7.0m−$6,675—−$1.1m−$1.1m−$2.7m
Capital spending——−$3−$2———−$58,063−$11,545−$856,853
Free cash flow——$15.6m$558,112$7.0m−$6,675—−$1.2m−$1.1m−$3.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−$13,324−$803−$22,525−$14,749−$21,961−$16,680−$15,025−$3,780
Net income−$13,229−$849−$22,575−$14,749−$21,961−$16,680−$15,025−$3,780
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets———————$100,000
Debt———————$58,780
Shareholders' equity———————−$58,780

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-58.2%-13.3%-36.4%
Net income-86.3%-33.6%-43.5%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2015FY2014
Price to earnings-8.7-1835.20.1———
Price to sales———0.00.00.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return300%3177%67%158%266%15%-35%-94%-26%-52%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.